Abstract:Tau and ɑ-synuclein aggregates are the main histopathological hallmarks present in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders. Intraneuronal hyperphosphorylated tau accumulation is significantly connected to the degree of cognitive impairment in AD patients. In particular, the longest 2N4R tau isoform has a propensity to rapidly form oligomers and mature fibrils. On the other hand, misfolding of ɑ-synuclein (α-syn) is the characteristic feature in PD and dementia with Lewy bodies (DLB). There is a strong crosstalk between the two prone-to-aggregation proteins as they coprecipitated in some brains of AD, PD, and DLB patients. Simultaneous targeting of both proteinaceous oligomers and aggregates is still challenging. Here, we rationally designed and synthesized benzothiazole- and indole-based compounds using the structural hybridization strategy between the benzothiazole N744 cyanine dye and the diphenyl pyrazole Anle138b that showed anti-aggregation activity towards 2N4R tau and ɑ-syn, respectively. The anti-aggregation effect of the prepared compounds was monitored using the thioflavin-T (ThT) fluorescence assay, while transmission electron microscopy (TEM) was employed to detect fibrils upon the completion of a time-course study with the ThT assay. Moreover, the photo-induced crosslinking of unmodified protein (PICUP) assay was used to determine the formation of oligomers. Specifically, compounds 46 and 48 demonstrated the highest anti-aggregation activity by decreasing the ThT fluorescence to 4.0 and 14.8%, respectively, against ɑ-synuclein. Although no noticeable effect on 2N4R tau oligomers, 46 showed promising anti-oligomer activity against ɑ-syn. Both compounds induced a significantly high anti-aggregation effect against the two protein fibrils as visualized by TEM. Moreover, compound 48 remarkably inhibited α-syn inclusion and cell confluence using M17D cells. Collectively, compounds 46 and 48 could serve as a basic structure for further optimization to develop clinically active AD and PD disease-modifying agents.

N-Benzyl, N-phenethyl and N-benzyloxybenzamide derivatives inhibit amyloid-beta (Aβ42) aggregation and mitigate Aβ42-induced neurotoxicity

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Discovery of small molecule benzothiazole and indole derivatives tackling tau 2N4R and a-synuclein fibrils

Structural Optimization and Biological Evaluation of Substituted Bisphenol A Derivatives As Beta-Amyloid Peptide Aggregation Inhibitors.

Identification of N-phenyl-3-methoxy-4-pyridinones As Orally Bioavailable H3 Receptor Antagonists and Β-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer's Disease.

Discovery of novel coumarin triazolyl and phenoxyphenyl triazolyl derivatives targeting amyloid beta aggregation-mediated oxidative stress and neuroinflammation for enhanced neuroprotection

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Discovery of Quinolinone Hybrids as Dual Inhibitors of Acetylcholinesterase and Aβ Aggregation for Alzheimer's Disease Therapy

Design and Synthesis of New Benzo[d]oxazole-Based Derivatives and Their Neuroprotective Effects on β-Amyloid-Induced PC12 Cells

Design, Synthesis, and Bioevaluation of Benzamides: Novel Acetylcholinesterase Inhibitors with Multi-Functions on Butylcholinesterase, Aβ Aggregation, and Β-Secretase.

Design, synthesis, and evaluation of 2-piperidone derivatives for the inhibition of β-amyloid aggregation and inflammation mediated neurotoxicity

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Novel inhibitors of AChE and Aβ aggregation with neuroprotective properties as lead compounds for the treatment of Alzheimer's disease

Synthesis, biological and computational evaluation of benzoxazole hybrid analogs as potential anti-Alzheimer's agents

Discovery of Compounds That Selectively Repress the Amyloidogenic Processing of the Amyloid Precursor Protein: Design, Synthesis and Pharmacological Evaluation of Diphenylpyrazoles

Design, synthesis, in vitro, and in silico study of benzothiazole-based compounds as a potent anti-Alzheimer agent

2-Phenylbenzothiazolyl iridium complexes as inhibitors and probes of amyloid β aggregation

N-methylbenzothiazolium based theranostics as fluorescence imaging and photo-oxidation agents for Amyloid-β

Design, Synthesis, and Biological Evaluation of 4‐aminopyrimidine or 4,6‐diaminopyrimidine Derivatives As Beta Amyloid Cleaving Enzyme‐1 Inhibitors

Inhibition of Amyloid Β Aggregation and Cytotoxicity by Berbamine Hydrochloride.